We sell no peptides.
Our answers are for sale to no one.
In a market where most “guidance” comes from someone who profits when you buy a compound, our independence is the product. It is the one thing a telehealth platform or compound seller structurally cannot claim.
We sell no compounds
DoseCraft does not manufacture, stock, ship, or sell any peptide. We have no inventory to move and no margin tied to you starting a protocol. A platform that profits from compound sales has a reason to nudge you toward use — we structurally do not.
Our answers are for sale to no one
No vendor pays to be graded up a lane. No brand sponsors a verdict. Our evidence lanes are assigned by the strength of the data and cannot be bought, period. The grading you see is the grading we'd give if no one were watching.
No prescriptions, no conflicts
We don't run a telehealth arm, write prescriptions, or take a cut of a clinic visit. Platforms that sell the consult and the compound make more when you use more. That conflict isn't in our model — we make the same whether you run a protocol or don't.
Why this is structural, not a slogan
A telehealth platform that prescribes and a vendor that ships both earn more when you use more. That incentive doesn’t make them dishonest — but it means their guidance can never be fully neutral, because their revenue moves with your dose.
DoseCraft’s revenue does not move with your dose. We make the same whether you run a protocol, taper one, or decide a compound isn’t for you. That is why we can label a hyped compound “Experimental” without flinching — and why our grading method is published in full.
Not medical advice — educational only. DoseCraft is an information and personal tracking platform. We do not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting any protocol.